An international group of experts led by the Comprehensive Cancer Center (CCC) at MedUni Vienna and University Hospital Vienna has established endpoints for clinical trials in patients with cancer and isolated metastases. The aim is to evaluate the benefits of modern therapies specifically targeting metastases using metrics that are particularly relevant to patients. The consensus paper, now published in The Lancet Oncology, marks a paradigm shift in cancer research.
Continue Reading this article here
